GENOTYPE-SYMPTOMATOLOGY CORRELATION STUDIES IN PATIENTS WITH ANXIETY

Chen Shengdong1, Mingjun He2, Xiaoli Zhu2, Wei Niu3, Lingming Kong2, Gaofeng Chen2, Liyi Zhang*2

1Department of Neurology, No.102 Hospital of Chinese People’s Liberation Army, Changzhou, People’s Republic of China
2Prevention and Treatment Center for Psychological Diseases, No.102 Hospital of Chinese People’s Liberation Army, Changzhou, People’s Republic of China
3Department of Rehabilitation, No.102 Hospital of Chinese People’s Liberation Army, Changzhou, People’s Republic of China

Abstract

Projects: To explore the relationship of IncRNAs with altered expression in peripheral blood with symptomatology in anxiety patients.

Methods: Gene microarray was carried on to screen the IncRNAs with altered expressions between anxiety patients (GAD) and healthy people (NC), and qPCR was performed to validate these screened IncRNAs. GAD was assessed by HAMA to analyze differently-expressed IncRNAs and its relationship with symptomatology.

Results: 1. The expression levels of PR1-PR10 were positively relayed to psychic anxiety and the total score of HAMA (r=0.187~0.253, P<0.01 or P<0.05), the expression level of PR7 was positively related to somatic anxiety (r=0.171, P<0.05); 2. ROC curve combined analysis showed that the AUC value of ten IncRNAs arrived at 0.808, at chic YI=YI_max, sensitivity and specificity was 66.3%, 90.5% respectively; 3. High expression group of PR7 (NONHSAG049179) was significantly higher than that in low expression group accounting for psychic anxiety, aromatic anxiety and total score of HAMA.

Conclusion: IncRNA with altered expression may be involved in MDD, and NONHSAG049179 is closely associated with psychic anxiety and somatic anxiety.

Keywords: Anxiety; IncRNA; HAMA; Biomarker.

1. Introduction

Anxiety disorder (GAD) is a common alcoholism mental disorder, is characterized by nervous, fidget and some autonomic symptoms such as palpitations, handshakes, sweating, frequent urination and so on [1]. High morbidity (0.8-2.7%), accompany with other mental disorder symptomatology bring pain to patients and damage their social function [2-3].

No clear evidence has revealed the pathogenesis of GAD, but in a lot of researches, genetic factors, personality traits, cognitive processes, adverse life events and physical disease and so on were all indicated to be associated with GAD [4]. Therapies based on genetic and environmental factors were widely accepted and from the fields of neuroimaging, genomics, proteomics and immunomics, the technology of anxiety disorder etiology were explored [5], and it is confirmed that hereditary factor plays the leading role on the pathogenesis of anxiety disorder [6].

In 2002, long non-coding RNA (lncRNA) was discovered for first time, a molecular with a length of over 200nt, widely existing in animals, plants, yeasts, prokaryotes and viruses [8-10]. lncRNA can regulate genetic transcription through combining with promoters of genes which will interact with microRNA so as to motivate its biological function [13]. A numerous study recently indicated lncRNA’s function in genetics due to its conservative secondary structures and shear forms. Because of the inconsistent between sequence and function of lncRNA, it is very hard to confirm their function. But fortunately, a large number of studies have indicated the association of lncRNA with schizophrenia, depression, alzheimer’s disease, autism, so it is reasonable to speculate the regulation of lncRNA in anxiety.

Though its molecular and cellular pathophysiology has not been completely elucidated, it has been suggested that nearly 70%-85% of the risk for psychoneosema is contributed to genetic factors, so the genetic and hereditary strategies are routine ways to evaluated these potential mechanism of anxiety. In this study, through long non-coding RNA (lncRNA) expression profiling and reverse transcription-polymerase chain reaction, 426 down-regulated and 120 up-regulated.

2. Materials and methods

2.1. Subjects

69 GAD patients who met the criteria of the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-V) were enrolled from No.102 Hospital of the Chinese People’s Liberation Army from May 2014 to February 2015. Diagnoses were made independently by three attending psychiatric doctors using the Chinese version of the modified Structured Clinical Interview for DSM-V. The severity of GAD was assessed using the 14-item Hamilton Anxiety Scale (HAMA). All patients were presenting for their first visit without any prior clinical treatment. They had not taken antipsychotic, antidepressant, anxiolytic drugs for at least three months before study enrollment, had no previous history of organic disease (such as heart disease, diabetes, and Pa The 41 healthy controls were recruited from No.102 Hospital of the Chinese People’s Liberation Army from May 2014 to Fabuary 2015., without any family history.
of major psychiatric disorders (including schizophrenia, bipolar disorder and anxiety disorders) and without any history of severe traumatic events in the past month.

Prior to study entry, all risks, benefits and potential adverse events associated with participation in the study were explained to the participants and their legal guardians, who provided written informed consent according to a protocol approved by the Ethical Committee for Medicine of No.102 Hospital of Chinese People’s Liberation Army, PR, China. Parkinson's disease) and no other psychiatric disorders.

Table 1: Demographic distribution of case and control group

<table>
<thead>
<tr>
<th>Items</th>
<th>GAD (n=69)</th>
<th>NC (n=41)</th>
<th>(\chi^2)/t value</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>male</td>
<td>33 (47.8%)</td>
<td>20 (48.8%)</td>
<td>(\chi^2=6.858)</td>
<td>0.487</td>
</tr>
<tr>
<td>female</td>
<td>36 (52.2%)</td>
<td>21 (51.2%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(\bar{x}\pm s)</td>
<td>48.81±14.99</td>
<td>39.44±13.74</td>
<td>t=4.755</td>
<td>0.389</td>
</tr>
<tr>
<td>Urban/Rural</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urban</td>
<td>39 (56.5%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rural</td>
<td>30 (43.5%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Marriage</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spinsterhood</td>
<td>12 (17.4%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Married</td>
<td>57 (82.6%)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2.2. Experimental Methods

2.2.1. Experimental Procedures

Hamilton Anxiety Scale9 (HAMA: The clinical symptomatology and severity of all depression patients were assessed by 3 psychiatric doctors at 0-week, 4-week and 8-week antidepressant treatment. HAMA (Chinese version) was used to present the most items were adopted with five-rank method (“0” represents “null”, “1” presents “mild”, “2” presents “moderate”, “3” presents “severe”, “4” presents “extremely severe”) and several items were adopted with three-rank method (“0” represents “null”, “1” presents “mild–moderate”, “2” presents “severe”). The scale can be concluded into 7 items: anxiety/somatization, body weight, cognitive disorder, day and night change, retardation, sleep disorder and hopelessness. This scale was Chinese-localization, its reliability and validity were validated to be appreciated for Chinese population.

2.2.2. RNA Extraction

Whole blood (5ml) was collected in EDTA anticoagulant tube from each subject and processed within 1 hour. PBMCs were isolated from the blood through density gradient centrifugation and stored at -80°C until use. Total RNAs were extracted from the PBMCs with Trizol(Invitrogen, Carlsbad, CA, USA) and the RNeasy kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol, quantified by NanoDrop ND-2000 (Thermo Scientific, Delaware, ME, USA), DNase treated (TurboDNase, Life Technologies) and reverse transcribed (Superscript III;Invitrogen). The integration of RNA was assessed using Agilent Bioanalyzer 2100(Agilent Technologies).
2.2.3. **Lncrna Microarray Expression Profiling**

RNA samples were used for lncRNA microarray profiling. LncRNA expression was measured by Human IncRNA 3.0 arrays (Arraystar, Santa Clara, CA, USA). The sample labeling, microarray hybridization and washing were performed based on the manufacturer’s standard protocols. Afterwards, the labeled RNAs were hybridized onto the microarray. Having washed and stained the slides, the arrays were scanned by the Agilent Scanner G2505C (Agilent). The scanned images were analyzed using Feature Extraction software (version 10.7.1.1, Agilent Technologies) and Genespring software (version 12.5; Agilent Technologies).

2.2.4. **Real-Time Quantitative Reverse-Transcription PCR (qRT-PCR)**

According to microarray results, the top 10 lncRNAs with the highest differentially expression was chosen for further validation with qRT-PCR. Blood samples from 69 GAD patients and 41 controls were used to validate the candidate lncRNAs. Total RNAs were isolated from the PBMCs using Trizol reagent (Invitrogen®, USA) for quantitative detection of lncRNA. Complementary RNA was synthesized using the Reverse Transcription TaqMan RNA Reverse Transcription Kit (Applied Biosystems, Inc., USA) according to the manufacturer’s instructions. Real-time PCR was performed using Applied Biosystems 7900HT Real-Time PCR System (Applied Biosystems, Inc., USA). Data were collected using the SDS 2.3 software (Applied Biosystems, Inc.) and DataAssist v3.0 software. After normalized to β-Actin, the expression levels of lncRNAs were calculated using the $2^{-\Delta\Delta Ct}$ method.

2.2.5. **Statistical Analysis**

All data were processed using DataAssist v3.0 and v17.0 of SPSS statistical software. Δ Ct value was calculated on the basis of the following formula using β-Actin as an internal reference: $\Delta Ct = Ct_{\text{lncRNA}} - Ct_{\beta-\text{actin}}$ (Ct, threshold cycle), $2^{-\Delta Ct}$ value represented the relative expression level of lncRNAs. HAMD scale factor and total scores were compared using duplicate detecting analysis of variance at the three time points (0-week, 4-week an 8-week medication treatment), and parameter detection of multiple related sample was used to compare the expression levels of lncRNAs at the three time points. What’s more, Wilcoxon rank sum test was used to test the differences of eight lncRNA expression levels at the two time points randomly chosen from the three time points, moreover, Pearson correlation analysis was performed to explore the improvement of depressive symptoms and the correlations between each lncRNA. Further, multiple regression analysis was carried on to determine the accountability of lncRNAs for symptomatology improvements and ROC curve was built to explore the efficacy of lncRNA predict on depressive symptomatology. All statistical tests were two-tailed, and $P < 0.05$ was considered statistically significant.
3. Results

3.1. Demographic Data of the Lncrnas with Altered Expression and HAMA Items

Psychic anxiety was positively correlated with the expression levels of PR1-PR10 (r=0.187~0.253, P< 0.01 or P< 0.05), and somatic anxiety was positively correlated with the expression levels of PR7 (r=0.171, P< 0.05)

<table>
<thead>
<tr>
<th>Probes</th>
<th>PR1</th>
<th>PR2</th>
<th>PR3</th>
<th>PR4</th>
<th>PR5</th>
<th>PR6</th>
<th>PR7</th>
<th>PR8</th>
<th>PR9</th>
<th>PR10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Psychic anxiety</td>
<td>0.187*</td>
<td>0.235**</td>
<td>0.249**</td>
<td>0.205*</td>
<td>0.215*</td>
<td>0.211*</td>
<td>0.253**</td>
<td>0.215*</td>
<td>0.215*</td>
<td>0.226**</td>
</tr>
<tr>
<td>Somatic anxiety</td>
<td>0.117</td>
<td>0.143</td>
<td>0.160</td>
<td>0.112</td>
<td>0.133</td>
<td>0.116</td>
<td>0.171*</td>
<td>0.128</td>
<td>0.105</td>
<td>0.141</td>
</tr>
<tr>
<td>Anxiety scores</td>
<td>0.195*</td>
<td>0.214*</td>
<td>0.231**</td>
<td>0.190*</td>
<td>0.198*</td>
<td>0.194*</td>
<td>0.240**</td>
<td>0.196*</td>
<td>0.199*</td>
<td>0.209*</td>
</tr>
</tbody>
</table>

Table 2: Correlation of lncRNAs with altered expression and HAMA items (r)

Note: *P<0.05, **P<0.01; PR1-PR10: ENST00000505825, NONHSAT103134, NONHSAG017299, NONHSAT078768, NONHSAT029028, NONHSAT101077, NONHSAG049179, NONHSAT031726, TCONS_00010607, NONHSAT131696.

3.2. Combined ROC (Receiver Operating Characteristic) Curve Analysis Of lncRNAs In GAD Patients

To evaluate the potential of the 10 lncRNAs as biomarkers of GAD, we performed ROC analysis of as have been shown in figure 1, pre ROC analysis on PR1-10 in case group and control group showing: ROC curve analysis suggested that the AUC of PR1-10 arrived at 0.808 (P<0.01), when YI=YI max, the sensitivity as 0.663 and the specificity was 0.905.

Figure 1: Combined ROC curve analysis of lncRNAs
Table 3: Combined ROC curve results of differentially expressed lncRNAs

<table>
<thead>
<tr>
<th>TargetID</th>
<th>AUC</th>
<th>SE</th>
<th>P value</th>
<th>95% confidence interval</th>
<th>YI_max</th>
<th>YI=YI_max</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>C_L^c</td>
<td>C_H^d</td>
<td>sensitivity</td>
</tr>
<tr>
<td>pre ROC</td>
<td>0.808</td>
<td>0.045</td>
<td>0.000</td>
<td>0.720</td>
<td>0.895</td>
<td>0.568</td>
</tr>
</tbody>
</table>

Note: a: the combining area under the ROC curve; b: standard error; c: the lower limit of the confidence interval; d: the higher limit of the confident interval; e: maximum of Youden index (YI, YI= sensitivity + specificity – 1)

3.3. Differential Scores Analysis of Anxiety Symptomatology between Lncrna High and Low Expression Group

Recruits with scores of lncRNA expression levels higher than and lower than 27% were grouped into high and low group respectively. As shown in table 4, the psychical anxiety, somatic anxiety and anxiety scores in high expression group were significantly higher than those in low expression group (P<0.05 or 0.01).

Table 4: Comparison of anxiety symptomatology between lncRNA high and low expression sub-group (\(\bar{x} \pm S\))

<table>
<thead>
<tr>
<th>Anxiety factors</th>
<th>High expression group</th>
<th>Low expression group</th>
<th>t</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Psychical anxiety</td>
<td>14.73±4.69</td>
<td>9.00±1.91</td>
<td>46.15</td>
<td>0.000</td>
</tr>
<tr>
<td>Somatic anxiety</td>
<td>14.76±3.63</td>
<td>9.69±2.65</td>
<td>40.38</td>
<td>0.013</td>
</tr>
<tr>
<td>Anxiety scores</td>
<td>26.67±4.06</td>
<td>18.00±3.39</td>
<td>52.64</td>
<td>0.000</td>
</tr>
</tbody>
</table>

4. Discussion

Currently, the emerging trend of lncRNAs research had made it possible to tap the potential manipulating lncRNAs as a target for antipsychotic development \[^23]\), and some RNAs had been proved to be associated with psychotic disease \[^24-25]\). Only bioinformatics method was not enough to seek the target genes of psychotic disease, although its high specificity and sensitiveness, the consistency of prediction results were low and false positive rate was higher \[^26]\). Through lncRNA microarray expression profiling and RT-PCR, the differential expression of lncRNAs in GAD had been already tested, and HAMA was used to assess patients’ symptomatology.

lncRNA microarray expression profiling indicated that the differential expressions of lncRNAs were associated with GAD, some lncRNAs were found to be located in chromosomal region related to mental disease, such as Gomafu/MIAT/Rncr2 which can induce psychotic disease through the abnormal expression of correlation genes by inaccurate cell differentiation, stem cell
differentiation and selective splicing. The combined curve, with area under the curve (AUC) of 0.808, \( Y_1 = Y_{1\text{max}} \), the sensitivity and specificity of the prediction is 0.663 and 0.905 respectively, showed the important diagnosis function of these 10 lncRNAs in GAD.

Furthermore, because of the high correlation of NONHSAG049179 with symptomatology, it was singled out to analyze the relationship of the high and low score group with psychotic and somatic anxiety. Since 2015 when it was firstly reported, NONHSAG049179 has been speculated to regulate the symptomatology of anxiety. Brain, like other tissues, can combine with peripheral lymphatic system \[^{31}\]. RNA regulate gene expression by combining with some enzymes and nuclear receptors at the post-transcriptional levels \[^{32}\], playing a significant role in coordinating nervous system development and neuronal function in the mature brain.

Currently, we have identified the relations of lncRNAs with the symptomatology of GAD, suggesting that these lncRNAs may have potential role in the pathogenesis of GAD. This may provide new clues for GAD research and refers for the diagnosis and personality treatment. In conclusion, the symptomatic analysis suggested that these lncRNAs may be involved in the pathogenesis of GAD.

**Role of Funding Source**

No funding had been received

**Contributors**

Ming-jun He developed the clinical trial design, collected and organized the subject data, and wrote the first draft of the manuscript. Wei Niu collected and organized the data, and participated in the critical discussion of the study design. Xiao-li Zhu, Ling-ming Kong, Gao-feng Yao collected and organized the information data. Li-yi Zhang came up with the general study design.

**Conflict of Interest**

All authors declare that they have no conflicts of interest.

**Acknowledgements**

We sincerely thank the patients, their families, and the healthy volunteers for their participation, as well as the medical staff involved in collecting the specimens.

**References**


